Onoact (landiolol) / Ono Pharmaceutical - LARVOL DELTA

Landiolol or a perioperative care bundle? Interpreting POAF prevention after OPCAB. (PubMed, Gen Thorac Cardiovasc Surg) - No abstract available

Journal

Beta-Blockers for the Treatment of Arrhythmias: Which Drug for Which Arrhythmia? A State-of-the-Art Narrative Review. (PubMed, Am J Cardiovasc Drugs) - "In adrenergically mediated inherited syndromes, namely catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, nonselective agents and especially nadolol are clearly superior to beta1-selective agents, and the same principle appears to extend to ventricular electrical storm, in which propranolol has outperformed metoprolol in a randomized comparison. In acute care, pharmacokinetics dominate, and the ultra-short-acting agents esmolol and landiolol permit a degree of titration that longer-acting drugs cannot match. In patients with heart failure and reduced ejection fraction, carvedilol, metoprolol succinate, and bisoprolol should be preferred irrespective of arrhythmia subtype because of their established mortality benefit. Conversely, beta1-selective agents, including the highly selective agent nebivolol, improve tolerability in bronchospastic disease, although this reflects respiratory tolerability rather than any demonstrated antiarrhythmic..."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Ventricular Tachycardia

Use of landiolol in septic shock patients with new onset of atrial fibrillation: a European Delphi consensus. (PubMed, Crit Care) - "This Delphi consensus provides pragmatic, physiology-driven recommendations for the management of NOAF in septic shock, supporting clinical decision-making in complex real-world settings where evidence remains limited."

Journal • Anesthesia • Atrial Fibrillation • Cardiovascular • Critical care • Heart Failure • Septic Shock

Microaxial Flow Pump and Ivabradine for Tachycardia-Induced Cardiogenic Shock Caused by Automatic Atrial Tachycardia. (PubMed, JACC Case Rep) - "A microaxial flow pump may provide hemodynamic support, facilitating safe rate control and myocardial recovery in TIC complicated by cardiogenic shock. Ivabradine may be useful when beta-blockers are difficult to initiate."

Journal • Cardiomyopathy • Cardiovascular • Heart Failure

Effectiveness of Intravenous Landiolol for Acute Management of Pediatric Supraventricular Tachycardia: Post-Hoc Analysis of LANDI-PED Trial (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Retrospective data • Cardiovascular • Pediatrics • Ventricular Tachycardia

Clinical Utility and Length of Stay Impacts of Landiolol for Supraventricular Tachyarrhythmias in US Intensive Care Settings (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Critical care • Ventricular Tachycardia

Comparative efficacy of landiolol and bisoprolol transdermal patch in patients with sepsis-related tachycardia: a retrospective cohort study. (PubMed, J Intensive Care) - "Landiolol and the bisoprolol transdermal patch achieved comparable 24-h HR control in the overall cohort of sepsis patients with tachycardia. A higher rate of HR control with landiolol was observed in patients with septic shock. The effect of these agents on mortality remains unclear, and further studies are warranted."

Journal • Retrospective data • Cardiovascular • Critical care • Infectious Disease • Septic Shock

Efficacy and safety of landiolol in patients with refractory ventricular arrhythmia and electrical storm: a single-center experience (ESC 2026) - "Landiolol demonstrated significant clinical efficacy in suppressing refractory VAs while maintaining a favorable safety profile in a high-risk cohort, as evidenced by low rates of treatment-limiting hypotension and bradycardia. These findings suggest that landiolol may be safely integrated into multimodal anti-arrhythmic strategies; however, prospective randomized trials are warranted to validate these retrospective observations."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Myocardial Infarction • Ventricular Tachycardia

Electrical storm after percutaneous coronary intervention for subacute anterior myocardial infarction with heart failure, treated with multidisciplinary therapy. (PubMed, BMJ Case Rep) - "Continuous VF, unresponsive to multiple direct current shocks, was finally terminated by direct-current shock after landiolol administration. Subsequent percutaneous stellate ganglion blocks stabilised the arrhythmia, allowing successful weaning from mechanical circulatory support."

Journal • Acute Coronary Syndrome • Anesthesia • Back Pain • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Musculoskeletal Pain • Myocardial Infarction • Pain • Pulmonary Disease

Comparative fluorimetric strategies for determination of landiolol hydrochloride using native fluorescence and green synthesized silver nanoparticles. (PubMed, Sci Rep) - "Selectivity is improved through preferential adsorption of landiolol on the AgNP surface and a large Stokes shift that minimizes interference from UV-absorbing matrix components. The resulting enhanced sensitivity and reduced matrix interference make this method a powerful tool for ultra-trace, selective, and sustainable determination of landiolol in pharmaceutical formulations and human plasma, demonstrating its suitability for routine quality control and bioanalytical applications."

Journal

PI2020_843_0057: Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractlity: an open label prospective randomized study (clinicaltrialsregister.eu) - P2/3 | N=360 | Recruiting | Sponsor: Centre Hospitalier Universitaire Amiens Picardie | Not yet recruiting ➔ Recruiting

Enrollment open • Septic Shock

Physiology-Guided Heart Rate Modulation in Cardiogenic Shock With Myocardial Bridging: Reversing the Inotrope Paradox. (PubMed, Catheter Cardiovasc Interv) - "After revascularization, the patient devoped cardiogenic shock requiring norepinephrine and dobutamine, but remained haemodinamically unstable, with persistent tachycardia, low cardiac index, reduced stroke volume index, and progressive respiratory failure...Low-dose landiolol, an ultra-short-acting and highly β1-selective blocker, was introduced under continuous haemodynamic monitoring...In this setting, physiology-guided heart rate reduction may restore coronary flow dynamics and improve systemic output. In selected patients with cardiogenic shock and myocardial bridging, ultra-short-acting β1-blockade may represent a targeted strategy to reverse tachycardia-mediated haemodynamic deterioration and support a diastole-centered approach to resuscitation."

Journal • Cardiovascular • Myocardial Infarction • Respiratory Diseases

Intraoperative landiolol hydrochloride use for prevention of postoperative atrial fibrillation with off-pump coronary artery bypass graft surgery (ILUPAF-OPCAB) study. (PubMed, Gen Thorac Cardiovasc Surg) - "Short-term perioperative administration of landiolol hydrochloride was associated with a lower incidence of POAF after OPCAB without an increase in perioperative complications. While further prospective randomized studies are needed, this simplified protocol may offer a safe, feasible, and potentially cost-favorable strategy for POAF prevention after cardiac surgery."

Journal • Atrial Fibrillation • Cardiovascular

A scoping review of the evidence supporting antiarrhythmic use after paediatric cardiac surgery. (PubMed, Cardiol Young) - "Although antiarrhythmics are commonly used in children after cardiac surgery, randomised trials with standardised endpoints to guide choice of therapy are lacking. Pragmatic trials to generate real-world data should be considered to further evaluate the safety and efficacy of various antiarrhythmics in this population."

Journal • Review • Cardiovascular • Pediatrics

Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients. Comment on Br J Anaesth 2026; 136: 65-73. (PubMed, Br J Anaesth) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular

Efficacy and safety of landiolol in patients with refractory ventricular arrhythmia and electrical storm: A single-center experience. (PubMed, Kardiol Pol) - No abstract available

Journal • Cardiovascular

Paroxysmal supraventricular tachycardia associated with dexmedetomidine withdrawal in an adult liver transplant recipient: A case report. (PubMed, World J Crit Care Med) - "Dexmedetomidine withdrawal should be considered in adult ICU patients presenting with unexplained tachyarrhythmia. Careful tapering and multimodal sedation strategies are essential when prolonged dexmedetomidine administration is anticipated."

Journal • Anesthesia • Cardiovascular • CNS Disorders • Critical care • Hypertension • Mood Disorders • Psychiatry • Septic Shock • Sleep Disorder • Transplantation • Ventricular Tachycardia

Treatment of supraventricular arrhythmias in critical care patients with sepsis. (PubMed, Front Cardiovasc Med) - "The Propafenone vs. Amiodarone for Supraventricular Arrhythmias in Septic Shock trial, the only double-blind randomized comparison of these agents, showed similar 24-hour cardioversion rates but faster cardioversion and fewer recurrences with propafenone, with treatment effects strongly modified by left atrial volume index. Trials of ultra-short acting beta-blockers demonstrated reliable heart-rate control but heterogeneous and fragile mortality signals, with the suggested benefit largely driven by single-center esmolol data and not consistently reproduced in multicenter landiolol studies. Evidence for digoxin and magnesium supports primarily adjunctive roles rather than first-line rate- or rhythm-control strategies. No study has evaluated vernakalant specifically in sepsis, limiting the evidence for its use in hemodynamically unstable patients...Overall, current evidence supports prioritizing correction of triggers and individualized selection of a rate- vs...."

Journal • Review • Acute Respiratory Distress Syndrome • Atrial Fibrillation • Cardiovascular • Critical care • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Septic Shock

The present and future of antiarrhythmic drugs. (PubMed, JRSM Cardiovasc Dis) - "Flecainide, propafenone, and dronedarone have demonstrated their reliable efficacy and safety, even in patients with structural heart disease, which should allow clinicians to reduce their reliance on amiodarone. Previous concerns regarding the proarrhythmic risk of dofetilide and ibutilide are currently managed through careful patient selection and adequate QT interval monitoring. Novel targeted AADs are advancing through the development pipeline, of which etripamil and landiolol have already been approved. Other emerging drugs, such as SK channel blockers (AP30663 and AP31969), RyR2 blockers, CaMKII inhibitors, and TASK-1 blockers (doxapram), are aligned with the new paradigm of atrial fibrillation that focuses on triggers and re-entry...Developing concepts such as atrial cardiomyopathy allows clinicians to characterize substrate objectively, in order to assess disease severity and individualize antiarrhythmic treatment. The future of antiarrhythmic therapy will be..."

Journal • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Heart Failure

Landiolol for atrial fibrillation after cardiac surgery: from prevention to treatment. (PubMed, Anaesth Crit Care Pain Med) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular

Landiolol in perioperative and critical care: evidence, patient selection, and practical titration for targeted heart rate control: a narrative review. (PubMed, J Anesth Analg Crit Care) - "Overall, current evidence supports landiolol as a potentially useful option for acute heart rate control and selected cases of septic tachycardia. Nevertheless, given the heterogeneity of critically ill populations and the absence of clear outcome benefits in large randomized trials, its use should remain individualized and guided by careful hemodynamic monitoring, with particular attention to appropriate patient selection."

Journal • Review • Atrial Fibrillation • Cardiovascular • Critical care • Infectious Disease • Septic Shock • Ventricular Tachycardia

LANTA-P: LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery (clinicaltrials.gov) - P4 | N=114 | Recruiting | Sponsor: Insel Gruppe AG, University Hospital Bern | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2025 ➔ Apr 2026

Enrollment open • Trial initiation date • Cardiovascular

A Pharmacokinetic Study of Landiolol Hydrochloride for Injection in Chinese Healthy Participants (ChiCTR) - P=N/A | N=12 | Sponsor: Clinical Trial Center of Third Xiangya Hospital of Central South University; Third Xiangya Hospital, Central South Univer

New trial • Cardiovascular

Comparison of Landiolol and Verapamil for Postoperative Atrial Fibrillation: A Prospective Randomized Study. (PubMed, Circ Rep) - "Landiolol achieved higher sinus rhythm conversion at 8 h (73.3% vs 16.7%; P=0.0016), but not at 12 h. No differences were observed in recurrence, adverse events, or intensive care unit stay. Landiolol facilitates earlier rhythm conversion without clear short-term clinical benefit."

Journal • Atrial Fibrillation • Cardiovascular • Critical care

Could Esmolol/Landiolol Infusion During Pulsed Field Ablation of Atrial Fibrillation Have Averted Takotsubo Syndrome? (PubMed, JACC Case Rep) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular